Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib

Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib

Recent clinical trials have shown promising results for the next-generation Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib in the treatment of multiple sclerosis (MS). BTK has a central role in signaling pathways that govern the development of B cells. Whether and how BTK activity shapes B cel...

Full description

Bibliographic Details
Main Authors: Liza Rijvers, Jamie van Langelaar, Laurens Bogers, Marie-José Melief, Steven C. Koetzier, Katelijn M. Blok, Annet F. Wierenga-Wolf, Helga E. de Vries, Jasper Rip, Odilia B.J. Corneth, Rudi W. Hendriks, Roland Grenningloh, Ursula Boschert, Joost Smolders, Marvin M. van Luijn
Format: Article
Language:English
Published: American Society for Clinical investigation 2022-08-01
Series:JCI Insight
Subjects:
Autoimmunity
Immunology
Online Access:https://doi.org/10.1172/jci.insight.160909

Internet

https://doi.org/10.1172/jci.insight.160909

Similar Items